Roy; Marie-Odile

Patent Applications and Registrations

Patent applications and USPTO patent grants for Roy; Marie-Odile.The latest application filed is for "novel chiral n-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective nk-3 receptor antagonists, phar".

Company Profile

6.11.12

Roy; Marie-Odile - Paris FR
Roy; Marie-Odile - Brussels N/A BG

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazi- nes as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof Grant 10,941,151 - Hoveyda , et al. March 9, 2	2021-03-09
Novel Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines As Selective Nk-3 Receptor Antagonists, Phar App 20200283447 - Hoveyda; Hamid R. ; et al.	2020-09-10
Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-A]pyrazi- nes as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof Grant 10,683,295 - Hoveyda , et al.	2020-06-16
Novel Nk-3 Receptor Selective Antagonist Compounds, Pharmaceutical Composition And Methods For Use In Nk-3 Receptors Mediated Di App 20200125564 - Hoveyda; Hamid R. ; et al.	2020-04-23
NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders Grant 10,544,150 - Hoveyda , et al. Ja	2020-01-28
Novel Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines As Selective Nk-3 Receptor Antagonists, Pharmaceutical Composition, Methods For Use In Nk-3 Receptor Mediated Disorders And Chiral Synthesis Thereof App 20190023711 - Hoveyda; Hamid R. ; et al.	2019-01-24
Chiral N-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyraz- ines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof Grant 10,065,961 - Hoveyda , et al. September 4, 2	2018-09-04
NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders Grant 10,065,960 - Hoveyda , et al. September 4, 2	2018-09-04
Novel Nk-3 Receptor Selective Antagonist Compounds, Pharmaceutical Composition And Methods For Use In Nk-3 Receptors Mediated Disorders App 20180194772 - Hoveyda; Hamid R. ; et al.	2018-07-12
NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders Grant 9,926,325 - Hoveyda , et al. March 27, 2	2018-03-27
NOVEL CHIRAL N-ACYL-5,6,7,(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS AND CHIRAL SYNTHESIS THEREOF App 20170029429 - Hoveyda; Hamid ; et al.	2017-02-02
Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazi- nes as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof Grant 9,475,814 - Hoveyda , et al. October 25, 2	2016-10-25
Novel Nk-3 Receptor Selective Antagonist Compounds, Pharmaceutical Composition And Methods For Use In Nk-3 Receptors Mediated Disorders App 20150315199 - Hoveyda; Hamid R. ; et al.	2015-11-05
Novel Nk-3 Receptor Selective Antagonist Compounds, Pharmaceutical Composition And Methods For Use In Nk-3 Receptors Mediated Disorders App 20140371218 - Hoveyda; Hamid R. ; et al.	2014-12-18
NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders Grant 8,871,761 - Hoveyda , et al. October 28, 2	2014-10-28
NOVEL CHIRAL N-ACYL-5,6,7(8-SUBSTITUTED)-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR MEDIATED DISORDERS AND CHIRAL SYNTHESIS THEREOF App 20140275097 - Hoveyda; Hamid R. ; et al.	2014-09-18
Methods of identifying a modulator that inhibits the binding between Epstein-Barr virus induced receptor 2 and cholesterol derived ligands Grant 8,497,075 - Baumgarten , et al. July 30, 2	2013-07-30
Novel Nk-3 Receptor Selective Antagonist Compounds, Pharmaceutical Composition And Methods For Use In Nk-3 Receptors Mediated Disorders App 20130023530 - Hoveyda; Hamid R. ; et al.	2013-01-24
Organic Compounds App 20110243923 - Baumgarten; Birgit ; et al.	2011-10-06
Ligand for G-protein coupled receptor GPR72 and uses thereof Grant 7,824,866 - Hannedouche , et al. November 2, 2	2010-11-02
Ligand for G-protein coupled receptor GPR72 and uses thereof App 20080274124 - Hannedouche; Sebastien ; et al.	2008-11-06

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.